NeoGenomics, Inc. (NEO) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Jun 12, 2026
Current Price
$11.15
Price Target
$19.00
Target Range
$13.00 — $25.00
Analyst Rating
Buy
Forward P/E61.9x
Trailing P/E-2.7x
Forward PEG—
Implied Growth+104.7%
Median Target$19.00
Analyst Spread63.2%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$13
+16.6%
Consensus
$19
+70.4%
Bull Case
$25
+124.2%
NEO Price Target Analysis
Updated June 13, 2026As of June 13, 2026, NeoGenomics, Inc. (NEO) has a Wall Street consensus price target of $19.00, based on estimates from 29 covering analysts. With the stock currently trading at $11.15, this represents a potential upside of +70.4%. The company has a market capitalization of $290M.
Analyst price targets range from a low of $13.00 to a high of $25.00, representing a 63% spread in expectations. The median target of $19.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 23 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NEO trades at a trailing P/E of -2.7x and forward P/E of 61.9x. Analysts expect EPS to grow +104.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+21.2%
Avg Forward P/E102.1x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SLNOSoleno Therapeutics, Inc. | $2.8B | $53.01 | $80.00 | +50.9% | Buy | 13.9x | 13 |
 CDNACareDx, Inc | $1.2B | $22.97 | $24.00 | +4.5% | Buy | 24.6x | 13 |
 NTRANatera, Inc. | $30.4B | $212.07 | $261.00 | +23.1% | Buy | — | 27 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
 LHLabcorp Holdings Inc. | $21.9B | $266.16 | $311.33 | +17.0% | Buy | 14.8x | 35 |
 DGXQuest Diagnostics Incorporated | $22.5B | $203.06 | $220.57 | +8.6% | Hold | 18.9x | 34 |
 MYRGMYR Group Inc. | $6.9B | $445.72 | $412.67 | -7.4% | Hold | 39.0x | 21 |
 FLGTFulgent Genetics, Inc. | $556M | $18.68 | $15.00 | -19.7% | Buy | — | 9 |
 PGNYProgyny, Inc. | $2.1B | $26.63 | $30.33 | +13.9% | Buy | 20.8x | 20 |
 CGENCompugen Ltd. | $193M | $2.04 | $4.50 | +120.6% | Buy | — | 14 |
Upside Potential Comparison
CGENSLNONTRALHPGNYDGXCDNAEXASWhat if you invested $1,000 in NEO 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in NEO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs NEO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationNEO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowNEO — Frequently Asked Questions
Quick answers to the most common questions about buying NEO stock.
What is the NEO stock price target for 2026?
The consensus Wall Street price target for NEO is $19, representing 70.4% upside from the current price of $11.15. With 29 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is NEO a buy, sell, or hold?
NEO has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 23 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies 70.4% upside from current levels.
Is NEO stock overvalued or undervalued?
At a forward P/E of 61.9444x, NEO trades at a premium valuation. The consensus price target of $19 (70.4% upside) suggests analysts still see growth justifying the multiple.
How high can NEO stock go?
The most bullish Wall Street analyst has a price target of $25 for NEO, while the most conservative target is $13. The consensus of $19 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover NEO stock?
NEO is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 22 have Buy ratings, 5 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the NEO stock forecast?
The 12-month NEO stock forecast based on 29 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $13 (bear case) to $25 (bull case). The median consensus rating is "Buy".
What is NEO's forward P/E ratio?
NEO trades at a forward P/E ratio of 61.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy NEO stock?
Wall Street analysts are very optimistic on NEO, with a "Buy" consensus rating and $19 price target (70.4% upside). 23 of 29 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do NEO price targets vary so much?
NEO analyst price targets range from $13 to $25, a 63% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground.